Sepsis and neutropenia induced by clozapine  by Melzer, M. et al.
6 0 4  C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  V o l u m e  4 N u m b e r  1 0 ,  October  1998  
Sepsis and neutropenia induced by clozapine 
CIin Micvobiol Infect 1998; 4: 604-605 
M .  Melzer', E K. Hassanyeh*, M.  H.  Snow' and E.  L. C. Ong'* 
Departments of 'Infection and Tropical Medicine and *Psychiatry, Newcastle General Hospital, 
Newcastle upon Tyne NE4 6BE, UK 
*Tel: +44 191 273 8811 Fax: f44  191 273 0900 E-mail: e.l.c.ong@ncl.ac.uk 
Accepted 24 April 1998 
A 34-year-old man with a chronic schizoaffective 
disorder treated with droperidol 10 mg once daily and 
clozapine 350 mg at night was transferred to our 
infectious diseases unit for barrier nursing following a 
weekly full blood count which revealed neutropenia 
(white cell count 1.9X 109/L; neutrophil count 
1.24X1OY/L). He had failed to respond to treatment 
with droperidol alone, although he had shown signs of 
clinical improvement with the addition of clozapine 9 
weeks previously. Full blood counts had been per- 
formed weekly and these are illustrated in Figure 1. 
O n  admission he was calm and co-operative and 
had no signs of infection. Nasal and throat swabs were 
negative. Bone marrow aspirate and trephine biopsy 
revealed an almost complete absence of granulocyte 
precursors. Prophylactic itraconazole 400 mg once a 
night was commenced in addition to granulocyte 
colony-stimulating factor (G-CSF) 42 M U  subcutane- 
ously once daily. 
Three days later he became febrile, and blood 
cultures taken 24 hr before the onset of symptoms grew 
a fully sensitive group G streptococcus and coagulase- 
negative staphylococcus. Chest X-ray was normal and 
no organisms were grown from the urine. Before 
sensitivities were known, intravenous teicoplanin 
200 mg once daily and ceftazidime 2 g three times a day 
was commenced and his temperature settled. Seven 
days later he became febrile but he remained clinically 
well. Repeated examination revealed no localizing 
signs of infection and repeat cultures were negative. O n  
day 17 he became hypoxic, hypotensive (blood pressure 
70/30) and oliguric, though this improved with 
intravenous rehydration. Intravenous ciprofloxacin and 
metronidazole were substituted for ceftazidime. The 
patient was transferred to the intensive care unit for 
continuous positive airways pressure (CPAP), inotropic 
support and careful monitoring of his fluid balance. 
Further cultures of blood and urine were again 
negative . 
A chest X-ray performed at this time revealed 
shadowing at the right base and mid-zone, and a 
bronchoscopy and lavage revealed no organisms. 
Intravenous amphotericin was commenced to cover the 
possibility of fungal infection. In view of the patient's 
deteriorating clinical condition, tazobactam 4.5 g three 
times daily was added to treatment. His G-CSF was 
changed to granulocyte macrophage colony-stimulat- 
ing factor (GM-CSF) 80 000 u/kg once daily, as he 
remained profoundly neutropenic. Although well 
oxygenated, he became agitated and began to voice 
persecutory delusions, threatening to pull out his 
central line and catheter. Mentally, he became calmer 
on regular droperidol 10 mg four times a day. 
Gradually, his clinical condition stabilized, although he 
became anemic and his plasma albumin fell to 19 g/L. 
He required blood transfusions, intravenous albumin 
and frusemide as additional supportive therapy. 
O n  day 29 his neutrophil count returned to 
normal, although he remained pyrexial and subse- 
quently developed a maculopapular rash. This was 
thought to be due to a drug reaction, and on cessation 
of all treatment his temperature and rash resolved. He 
was transferred back to a psychiatric unit 35 days 
following admission. 
Clozapine-induced neutropenia and granulo- 
cytopenia are well-documented complications, and 
licensing in the UK was agreed in 1989, on the under- 
standing that weekly full blood counts were performed 
for eighteen weeks following the initiation of treat- 
ment. N-Desmethylclozamine, a clozapine metabolite, 
is thought to accumulate and suppress hemopoiesis 111. 
No clinical evidence of drug-induced antineutrophil or 
antimyeloid precursor antibodies has been found. The 
drug manufacturer Sandoz claimed that, over the last 5 
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Figure 1 Results from the day of admssion. 
years, 48 out of 6316 patients developed agranulo- 
cytosis during this period, with two fatalities from 
uncontrolled sepsis. Transient neutropenia occurs more 
commonly and can often be arrested by the cessation 
of treatment [ 2 ] ,  although agranulocytosis may ensue, 
with a higher risk of sepsis and mortality. In one report 
the early use of G-CSF shortened the length of 
neutropenia, on average from 15 to 8 days [3]. Addition 
of GM-CSF may also contribute to the recovery of 
neutrophil counts [4]. 
Clozapine is useful adjuvant therapy for patients 
failing to respond to conventional neuroleptic therapy. 
Treatment is not without risk, and developments such 
as screening for myelotoxic metabolites [5] may help to 
prevent potentially life-threatening agranulocytosis and 
sepsis arising in the future. 
The cost, however, of treating a case of clozapine- 
induced agranulocytosis is undoubtedly high and it is 
potentially associated with a high mortality. 
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